Clinical Trials
- Lymphoma, Leukemia
Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
- Immune System, Infectious Disease
Multicenter, Open Label, Phase 3 Trial of ATA129 for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
- GenderBoth
- Colorectal Cancer, Breast Cancer, Gynecological Cancers, Stomach and Esophagus, Lymphoma, Kidney Cancer, Head and Neck Cancers, Liver Cancer, Lung Cancer, Melanoma, Thyroid and Other Endocrine Cancers, Other Cancers, Bladder Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma Cancers, Phase 1 Cancers, Cancer
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
- Lymphoma
test
- Lymphoma
test
- Lymphoma
test
- Myeloma
test
- Lymphoma
test
- Lymphoma
test
- Leukemia, Lymphoma, Phase 1 Cancers
test